CWI1-2 hydrochloride

Cat. No.: HY-153274A

CAS No.: 2408590-37-2

Molecular Formula: $C_{22}H_{18}Cl_4N_6O_3$

Molecular Weight: 556.23

Target: Apoptosis

Pathway: Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

CWI1-2 hydrochloride is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects[1].

In Vitro

CWI1-2 (0-1 μM, 24 h) hydrochloride has good anti-leukemic efficacy[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[1]

Cell Line:	MonoMac6, MOLM13
Concentration:	0-1 μM
Incubation Time:	24 h
Result:	Induced significant cell differentiation and apoptosis in a concentration-dependent manner in IGF2BP2-high cells but not in IGF2BP2-low cells. Reduced Gln uptake and impaired mitochondrial function, resulting in reduced ATP production in AML cells. Significantly inhibited the colony-forming ability of MA9-induced leukemic mouse blasts and greatly impairs the self-renewal of LSC/LIC.

In Vivo

CWI1-2 (5 mg/kg, i.v., once daily, 7-10 days) hydrochloride can significantly delay the onset of leukemia and prolong the survival time of BMT recipient B6.SJL (CD45.1) mice without any loss in body weight[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Hengyou Weng, et al. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022 Dec 12;40(12):1566-1582.e10.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA